KESETT

KESETT

Ketamine add-on therapy for Established Status Epilepticus Treatment Trial

|

1UG3NS131532-01A1


Status: Enrolling

Trial Updates


KESETT – New Resource in the Workbench

We have added a new resource to the KESETT workbench. You can find the archive of the slides presented at the monthly SIREN study coordinator meeting in the workbench under …

KESETT – Welcoming Our New Site Manager

Please join the SIREN CCC in welcoming our new KESETT Site Manager, Vincent Cervantes. Vincent will be the primary point of contact for KESETT site management questions. His contact is …

Overview


Generalized convulsive status epilepticus (long-lasting convulsive seizures) is a dangerous but common neurologic emergency; it can cause respiratory depression and permanent brain damage. KESETT is a phase III randomized, double-blind clinical trial to test whether ketamine (1 or 3 mg/Kg) added to standard therapy, levetiracetam (60mg/Kg), is more effective than levetiracetam alone in treating status epilepticus after benzodiazepines have failed.

Learn About KESETT

Presented by Robert Silbergleit

Slides

Contact


Emergency 24-Hour Study Hotline:

To be announced

Education (training, website access, material development, technical support):

Courtney Miller (coraymon@umich.edu) – Education Coordinator, or siren-contact@umich.edu

WebDCU Support (user account requests, technical support, CRF completion):

Sara Meyer (butlers@musc.edu) (843) 792-1599 & Riley Luckmann (luckmann@musc.edu) (843) 792-1599

Site Management & General Inquiries:

Vincent Cervantes (vcervant@umich.edu) or KESETT-contact@umich.edu

Finances:

Valerie Stevenson (vwillis@umich.edu)

For a comprehensive list of contacts:

SIREN COntact Page